Market Cap : 51.93 B | Enterprise Value : 80.5 B | P/E (TTM) : | P/B : 0.76 |
---|
NYSE:AGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:AGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
vs
industry |
vs
history |
||
---|---|---|---|
Cash-to-Debt | 0.21 |
86% of the 886 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.53 vs. NYSE:AGN: 0.21 ) Ranked among companies with meaningful Cash-to-Debt only. |
NYSE:AGN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.4 Max: 41.17 Current: 0.21 |
Equity-to-Asset | 0.62 |
53% of the 801 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.64 vs. NYSE:AGN: 0.62 ) Ranked among companies with meaningful Equity-to-Asset only. |
NYSE:AGN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27 Med: 0.63 Max: 0.91 Current: 0.62 |
Debt-to-Equity | 0.41 |
58% of the 540 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.32 vs. NYSE:AGN: 0.41 ) Ranked among companies with meaningful Debt-to-Equity only. |
NYSE:AGN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.29 Max: 1.68 Current: 0.41 |
Debt-to-EBITDA | -15.65 |
99.99% of the 522 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.83 vs. NYSE:AGN: -15.65 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
NYSE:AGN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.65 Med: 4.46 Max: 15.49 Current: -15.65 |
Piotroski F-Score: 6 |
|
Altman Z-Score: 0.74 |
|
Beneish M-Score: -2.39 |
|
WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
vs
industry |
vs
history |
||
---|---|---|---|
Operating Margin % | -3.40 |
82% of the 819 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.96 vs. NYSE:AGN: -3.40 ) Ranked among companies with meaningful Operating Margin % only. |
NYSE:AGN'
s Operating Margin % Range Over the Past 10 Years
Min: -14.8 Med: 2.28 Max: 14.12 Current: -3.4 |
Net Margin % | -25.88 |
79% of the 819 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.73 vs. NYSE:AGN: -25.88 ) Ranked among companies with meaningful Net Margin % only. |
NYSE:AGN'
s Net Margin % Range Over the Past 10 Years
Min: -28.83 Med: 5.43 Max: 102.76 Current: -25.88 |
ROE % | -5.93 |
72% of the 857 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.75 vs. NYSE:AGN: -5.93 ) Ranked among companies with meaningful ROE % only. |
NYSE:AGN'
s ROE % Range Over the Past 10 Years
Min: -11.23 Med: 6.44 Max: 19.24 Current: -5.93 |
ROA % | -3.34 |
70% of the 888 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.29 vs. NYSE:AGN: -3.34 ) Ranked among companies with meaningful ROA % only. |
NYSE:AGN'
s ROA % Range Over the Past 10 Years
Min: -4.33 Med: 3.67 Max: 11.31 Current: -3.34 |
ROC (Joel Greenblatt) % | -539.64 |
88% of the 869 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 12.64 vs. NYSE:AGN: -539.64 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
NYSE:AGN'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -547.05 Med: 2.26 Max: 39.38 Current: -539.64 |
3-Year Revenue Growth Rate | -7.00 |
92% of the 681 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.40 vs. NYSE:AGN: -7.00 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
NYSE:AGN'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14 Med: 17.35 Max: 54 Current: -7 |
3-Year EPS without NRI Growth Rate | -2.00 |
67% of the 657 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 10.20 vs. NYSE:AGN: -2.00 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
NYSE:AGN'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0 Med: 0.75 Max: 94.3 Current: -2 |
Manning & Napier Advisors, Inc 18,035 sh (+50.54%) Diamond Hill Capital 1,687 sh (+30.78%) Bernard Horn 21,989 sh (+26.45%) Tom Gayner 33,000 sh (+22.22%) Pioneer Investments 1,340,783 sh (+6.54%) Ken Fisher 5,314 sh (+4.22%) Jerome Dodson 183,000 sh (+3.39%) Jeff Auxier 8,010 sh (+0.63%) Mario Gabelli 71,323 sh (+0.51%) | David Carlson 470,000 sh (unchged) Robert Bruce 50,000 sh (unchged) Seth Klarman 2,432,603 sh (unchged) Leon Cooperman 295,188 sh (unchged) Eaton Vance Worldwide Health Sciences Fund 281,471 sh (unchged) | Andreas Halvorsen Sold Out Paul Tudor Jones Sold Out Steven Cohen Sold Out Joel Greenblatt Sold Out Vanguard Health Care Fund 11,426,334 sh (-2.19%) Frank Sands 5,428 sh (-2.25%) Private Capital 146,853 sh (-2.48%) NWQ Managers 164,265 sh (-4.61%) Scott Black 7,814 sh (-5.16%) Wallace Weitz 481,895 sh (-5.95%) First Pacific Advisors 9,700 sh (-6.73%) John Paulson 2,703,570 sh (-8.10%) David Tepper 2,509,619 sh (-14.56%) John Griffin 1,438,000 sh (-24.71%) Jim Simons 234,169 sh (-54.97%) |
Paul Tudor Jones 7,925 sh (New) George Soros 1,100 sh (New) Steven Cohen 449,776 sh (New) Caxton Associates 2,100 sh (New) Ken Fisher 7,015 sh (+32.01%) Bernard Horn 27,289 sh (+24.10%) Seth Klarman 2,964,203 sh (+21.85%) Wallace Weitz 523,810 sh (+8.70%) Jeff Auxier 8,495 sh (+6.05%) Frank Sands 5,618 sh (+3.50%) David Carlson 480,000 sh (+2.13%) Pioneer Investments 1,355,733 sh (+1.12%) Scott Black 7,884 sh (+0.90%) | Tom Gayner 33,000 sh (unchged) Robert Bruce 50,000 sh (unchged) | Leon Cooperman Sold Out Vanguard Health Care Fund 11,337,619 sh (-0.78%) Mario Gabelli 70,023 sh (-1.82%) First Pacific Advisors 9,500 sh (-2.06%) Private Capital 139,929 sh (-4.71%) Manning & Napier Advisors, Inc 16,960 sh (-5.96%) Diamond Hill Capital 1,540 sh (-8.71%) John Griffin 1,283,680 sh (-10.73%) NWQ Managers 136,976 sh (-16.61%) John Paulson 2,180,292 sh (-19.36%) David Tepper 1,888,188 sh (-24.76%) Jerome Dodson 115,075 sh (-37.12%) Jim Simons 63,169 sh (-73.02%) Eaton Vance Worldwide Health Sciences Fund 257,544 sh (-8.50%) |
Arnold Van Den Berg 162,205 sh (New) Mason Hawkins 2,297,386 sh (New) Larry Robbins 1,154,576 sh (New) Diamond Hill Capital 22,838 sh (+1382.99%) Jim Simons 726,269 sh (+1049.72%) Frank Sands 30,073 sh (+435.30%) Paul Tudor Jones 36,855 sh (+365.05%) David Tepper 3,465,862 sh (+83.55%) Robert Bruce 89,200 sh (+78.40%) NWQ Managers 225,549 sh (+64.66%) Jerome Dodson 188,775 sh (+64.05%) Seth Klarman 4,500,000 sh (+51.81%) Private Capital 175,694 sh (+25.56%) Wallace Weitz 650,315 sh (+24.15%) Jeff Auxier 9,995 sh (+17.66%) Vanguard Health Care Fund 13,216,673 sh (+16.57%) | David Carlson 480,000 sh (unchged) Tom Gayner 33,000 sh (unchged) Caxton Associates 2,100 sh (unchged) Bernard Horn 27,289 sh (unchged) | Scott Black Sold Out George Soros Sold Out Steven Cohen Sold Out Mario Gabelli 67,948 sh (-2.96%) Ken Fisher 6,494 sh (-7.43%) John Paulson 1,898,724 sh (-12.91%) Pioneer Investments 1,147,408 sh (-15.37%) First Pacific Advisors 2,500 sh (-73.68%) John Griffin 215,000 sh (-83.25%) Eaton Vance Worldwide Health Sciences Fund 139,059 sh (-46.01%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
---|---|---|---|---|---|---|---|---|
Vanguard Health Care Fund | 2017-12-31 | Add 16.57% | 0.67% | $163.58 - $210.98 | $ 158.51 | -12% | 13,216,673 | ![]() |
Seth Klarman | 2017-12-31 | Add 51.81% | 2.49% | $163.58 - $210.98 | $ 158.51 | -12% | 4,500,000 | ![]() |
David Tepper | 2017-12-31 | Add 83.55% | 2.43% | $163.58 - $210.98 | $ 158.51 | -12% | 3,465,862 | ![]() |
Mason Hawkins | 2017-12-31 | New Buy | 4.65% | $163.58 - $210.98 | $ 158.51 | -12% | 2,297,386 | ![]() |
John Paulson | 2017-12-31 | Reduce -12.91% | 1.04% | $163.58 - $210.98 | $ 158.51 | -12% | 1,898,724 | ![]() |
Wallace Weitz | 2017-12-31 | Add 24.15% | 0.89% | $163.58 - $210.98 | $ 158.51 | -12% | 650,315 | ![]() |
NWQ Managers | 2017-12-31 | Add 64.66% | 0.21% | $163.58 - $210.98 | $ 158.51 | -12% | 225,549 | ![]() |
Private Capital | 2017-12-31 | Add 25.56% | 0.94% | $163.58 - $210.98 | $ 158.51 | -12% | 175,694 | ![]() |
Arnold Van Den Berg | 2017-12-31 | New Buy | 3.6% | $163.58 - $210.98 | $ 158.51 | -12% | 162,205 | ![]() |
Robert Bruce | 2017-12-31 | Add 78.40% | 1.51% | $163.58 - $210.98 | $ 158.51 | -12% | 89,200 | ![]() |
Mario Gabelli | 2017-12-31 | Reduce -2.96% | $163.58 - $210.98 | $ 158.51 | -12% | 67,948 | ![]() | |
Ken Fisher | 2017-12-31 | Reduce -7.43% | $163.58 - $210.98 | $ 158.51 | -12% | 6,494 | ![]() | |
George Soros | 2017-12-31 | Sold Out | 0.01% | $163.58 - $210.98 | $ 158.51 | -12% | 0 | ![]() |
Vanguard Health Care Fund | 2017-09-30 | Reduce -0.78% | 0.05% | $202.66 - $256.15 | $ 158.51 | -32% | 11,337,619 | ![]() |
Seth Klarman | 2017-09-30 | Add 21.85% | 1.36% | $202.66 - $256.15 | $ 158.51 | -32% | 2,964,203 | ![]() |
John Paulson | 2017-09-30 | Reduce -19.36% | 1.73% | $202.66 - $256.15 | $ 158.51 | -32% | 2,180,292 | ![]() |
David Tepper | 2017-09-30 | Reduce -24.76% | 2.24% | $202.66 - $256.15 | $ 158.51 | -32% | 1,888,188 | ![]() |
Wallace Weitz | 2017-09-30 | Add 8.70% | 0.36% | $202.66 - $256.15 | $ 158.51 | -32% | 523,810 | ![]() |
Private Capital | 2017-09-30 | Reduce -4.71% | 0.27% | $202.66 - $256.15 | $ 158.51 | -32% | 139,929 | ![]() |
NWQ Managers | 2017-09-30 | Reduce -16.61% | 0.09% | $202.66 - $256.15 | $ 158.51 | -32% | 136,976 | ![]() |
Mario Gabelli | 2017-09-30 | Reduce -1.82% | $202.66 - $256.15 | $ 158.51 | -32% | 70,023 | ![]() | |
Ken Fisher | 2017-09-30 | Add 32.01% | $202.66 - $256.15 | $ 158.51 | -32% | 7,015 | ![]() | |
George Soros | 2017-09-30 | New Buy | 0.01% | $202.66 - $256.15 | $ 158.51 | -32% | 1,100 | ![]() |
Leon Cooperman | 2017-09-30 | Sold Out | 2.99% | $202.66 - $256.15 | $ 158.51 | -32% | 0 | ![]() |
Vanguard Health Care Fund | 2017-06-30 | Reduce -2.19% | 0.14% | $218.73 - $248.91 | $ 158.51 | -33% | 11,426,334 | ![]() |
John Paulson | 2017-06-30 | Reduce -8.10% | 0.76% | $218.73 - $248.91 | $ 158.51 | -33% | 2,703,570 | ![]() |
David Tepper | 2017-06-30 | Reduce -14.56% | 1.68% | $218.73 - $248.91 | $ 158.51 | -33% | 2,509,619 | ![]() |
Wallace Weitz | 2017-06-30 | Reduce -5.95% | 0.31% | $218.73 - $248.91 | $ 158.51 | -33% | 481,895 | ![]() |
NWQ Managers | 2017-06-30 | Reduce -4.61% | 0.03% | $218.73 - $248.91 | $ 158.51 | -33% | 164,265 | ![]() |
Private Capital | 2017-06-30 | Reduce -2.48% | 0.14% | $218.73 - $248.91 | $ 158.51 | -33% | 146,853 | ![]() |
Mario Gabelli | 2017-06-30 | Add 0.51% | $218.73 - $248.91 | $ 158.51 | -33% | 71,323 | ![]() | |
Tom Gayner | 2017-06-30 | Add 22.22% | 0.03% | $218.73 - $248.91 | $ 158.51 | -33% | 33,000 | ![]() |
Ken Fisher | 2017-06-30 | Add 4.22% | $218.73 - $248.91 | $ 158.51 | -33% | 5,314 | ![]() | |
Joel Greenblatt | 2017-06-30 | Sold Out | 0.01% | $218.73 - $248.91 | $ 158.51 | -33% | 0 | ![]() |
Symbol | Price | Yield | Description |
---|---|---|---|
AGNpA.PFD | 543.50 | 2.53 | 5 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A- |
Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 | |
---|---|---|
Compare: | XTER:MRK, TSE:4502, NYSE:ZTS, SHSE:600276, NAS:MYL, NSE:SUNPHARMA, TSE:4523, NYSE:TEVA, SHSE:600518, SHSE:600196, SZSE:000538, TSE:4507, XPAR:IPN, TSE:4508, NYSE:PRGO, OCSE:LUN, SZSE:000963, JSE:APN, XSWX:VIFN, HKSE:03320 » details | |
Traded in other countries: | A60.Germany, AGN N.Mexico, | |
Headquarter Location: | Ireland |
On the other side of the ledger, Allergan plc (NYSE:AGN) was the largest detractor from Fund performance during the fourth quarter and calendar year. Following the invalidation of dry eye drug Restasis’s patents in federal court in October, we once again tested the assumptions underlying our valuation scenarios. The earlier-than-expected loss of Restasis profits and more conservative forecasts for the company’s aesthetics franchise resulted in a downward revision to our base case estimate of intrinsic value. The drop in Allergan’s stock price, however, has been far more pronounced, so we added to our position at $173 during the quarter.
From Weitz Investment Management's Value Fund fourth-quarter commentary.
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Allergan shares finished 2016 on a higher note, following an otherwise challenging year. While revenues and earnings were shy of expectations and drug price regulation dominated headlines throughout much of the past year, the health of Allergan’s core underlying growth drivers gave us confidence to continue buying shares at increasingly attractive discounts during the fourth calendar quarter. Encouragingly, recent operating results have come in ahead of internal forecasts, and the company’s initial outlook for 2017 exceeded our expectations. Growth across Allergan’s therapeutic segment looks healthy, with the global aesthetics franchise demonstrating notable strength. Headwinds from legislative and regulatory developments continue to bear monitoring,
From Weitz Value Fund first quarter 2017 commentary.
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Following a brief post-election rally, the majority of the biopharmaceutical sector retreated to prior price levels as capital continued to flow out of healthcare and into industries seen as potential beneficiaries of policy shifts under the new administration. After downwardly revising future growth expectations in August and again in early November, Allergan has become a “show me” story. Patent challenges for Restasis (dry eye treatment) and Namenda XR (alzheimer’s drug) may continue to weigh on the stock in the near term, though each contributes only a small percentage of our estimate of the company’s overall intrinsic value. Over the next 3-5 years, we believe the company will have healthy mid-single digit (or better) operating profit growth. 80% of the company’s recently announced $10 billion accelerated share repurchase program is complete at an average price below $200 per share. We believe this will prove to be a prudent use of excess cash in the long run. Future capital deployment and late-stage pipeline success remain potential positives over the next 12 -24 months. We continue to believe Allergan shares present compelling value at current prices.
From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. One week after closing the sale of Actavis generics to Teva Pharmaceuticals, Allergan reported mildly disappointing top-line results for the quarter. Importantly, however, Allergan’s “core” products continue to grow nicely, with five of the company’s seven core therapeutic categories growing by double digits (in constant currency) versus the prior year. Our base case valuation of $350-360 per share does not depend on Allergan hitting CEO Brent Saunders’ goal of double- digit organic growth. However, strong, high single-digit organic sales growth appears achievable, as the company’s recently launched products continue to scale. One near-term positive of a lower share price is that Allergan’s $5 billion in share repurchases between now and year end will go further, and deployment of a portion of the company’s nearly $28 billion in cash remains a possible catalyst for the stock. The re-emergence of drug pricing as a political issue is not surprising to us as we enter the home stretch of the presidential election. We believe Secretary Clinton’s plan to control and eventually lower prescription drugs costs could negatively impact Allergan’s long-term earnings trajectory (perhaps by $2-3 per share on a base of $18), should she win the election, but with the stock at $240, we believe the risk of permanent loss is low. In short, Allergan’s risk/reward ratio (upside to base case vs. downside to low case) continues to be skewed in favor of the long-term owner.
Akarna Therapeutics TPV was a founding investor in Akarna in Q1 2015. Akarna focuses on the treatment of Nonalcoholic Steatohepatitis (NASH), also known as fatty liver disease. Akarna was attractive for several reasons:
The team at Akarna identified a potentially best-in-class lead candidate with an attractive pre-clinical profile in in vitro and animal studies. Akarna also secured a broad intellectual property portfolio around the lead compound family.
In August 2016, just 18 months after Akarna was founded, Allergan acquired the company for an upfront payment of $50 million and undisclosed potential clinical, regulatory, and commercial milestones. For Third Point Ventures, our share of the upfront payment reflects a total return of 3.1x our initial investment. If Allergan (NYSE:AGN) successfully develops and commercializes the Akarna drug, the total return on our investment could be meaningfully larger.
From Third Point's third-quarter 2016 commentary.
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. The dissolution of Allergan’s merger with Pfizer in April, delays in gaining Federal Trade Commission approval for the sale of its global generics business to TEVA and broader industry concern around prescription drug prices combined to push Allergan’s stock down by 26% during the first half of the calendar year. As we wrote in January, we like the stand-alone Allergan business without the generics business and believe the $ 40 billion sale to TEVA should soon close. There are a number of signs that growth in Allergan’s aesthetics franchise is accelerating, and the company’s key product launches – VIBERZI, VRAYLAR and KYBELLA – appear to be off to healthy starts. The combination of healthy organic growth, debt reduction and meaningful share repurchases should drive per share value creation over our investment horizon. We substantially increased the Fund’s Allergan position during the second quarter at attractive discounts to our business value estimate.
From Weitz Value Fund's Value second quarter 2016 commentary.
Our conviction to buy Allergan plc (NYSE:AGN) in the first quarter relied on differentiation of Allergan from its specialty pharmaceutical peers (Valeant, Endo, Mallinckrodt) given the quality of its asset mix (Botox, glaucoma drugs, breast implants, aesthetics, etc.) and its non-reliance on distasteful price increases for growth. Admittedly, we were aware of the potential upside to the Pfizer deal and were disappointed with the Treasury’s actions to stem tax inversions. Regardless, we were comfortable with Allergan as a stand-alone company, given the above base business married to the pending closure of the sale of Allergan’s generics portfolio to Teva for approximately $40 billion. This deal (pending over the next quarters) will help drive Allergan’s M&A efforts towards obtaining a more biotech like growth profile, which should both drive increases in top/bottom-line growth and expand the multiple at which investors are willing to value Allergan’s business. However, while our initial thesis remains intact, the entire specialty pharmaceutical space has re-rated given the above-mentioned bad actors. This has pressured the entire space, and we decided to exit specialty pharmaceuticals and focus on the more innovative biotech space going forward.
From Baron Opportunity Fund first quarter 2016 commentary.
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focused on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter pharmaceutical products. A combination of factors contributed to the decline in Allergan’s stock during the quarter, including continued discussions of potential drug price regulation, regulatory delays in closing the company’s sale of its generic drug operations to TEVA and uncertainty around the viability of the proposed merger with Pfizer (which, subsequent to quarter end, has officially been called off). We believe the risk of the TEVA transaction falling through is low, and the company’s collection of durable growth assets, management acumen and balance sheet optionality create multiple paths for durable shareholder value creation in the years ahead. We added to our position during the quarter.
From Weitz Funds' Research Fund commentary 1st quarter.
vs
industry |
vs
history |
||
---|---|---|---|
Forward PE Ratio | 10.10 |
88% of the 111 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 20.00 vs. AGN: 10.10 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
PB Ratio | 0.76 |
94% of the 843 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.96 vs. AGN: 0.76 ) Ranked among companies with meaningful PB Ratio only. |
AGN'
s PB Ratio Range Over the Past 10 Years
Min: 0.69 Med: 1.72 Max: 5.9 Current: 0.76 |
PS Ratio | 3.32 |
51% of the 784 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.25 vs. AGN: 3.32 ) Ranked among companies with meaningful PS Ratio only. |
AGN'
s PS Ratio Range Over the Past 10 Years
Min: 0.99 Med: 2.09 Max: 10.64 Current: 3.32 |
Price-to-Free-Cash-Flow | 10.76 |
83% of the 216 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 26.03 vs. AGN: 10.76 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
AGN'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.27 Med: 19.31 Max: 287.96 Current: 10.76 |
Price-to-Operating-Cash-Flow | 9.00 |
84% of the 289 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 18.21 vs. AGN: 9.00 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
AGN'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.06 Med: 15.18 Max: 93.15 Current: 9 |
EV-to-EBIT | -8.66 |
99.99% of the 599 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 19.78 vs. AGN: -8.66 ) Ranked among companies with meaningful EV-to-EBIT only. |
AGN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4 Med: 10.7 Max: 102.2 Current: -8.66 |
EV-to-EBITDA | -41.88 |
99.99% of the 623 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 16.59 vs. AGN: -41.88 ) Ranked among companies with meaningful EV-to-EBITDA only. |
AGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.1 Med: 12.6 Max: 106.9 Current: -41.88 |
EV-to-Revenue | 5.05 |
64% of the 810 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.38 vs. AGN: 5.05 ) Ranked among companies with meaningful EV-to-Revenue only. |
AGN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2 Med: 2.6 Max: 18.1 Current: 5.05 |
Shiller PE Ratio | 49.62 |
66% of the 230 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 36.11 vs. AGN: 49.62 ) Ranked among companies with meaningful Shiller PE Ratio only. |
AGN'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.96 Med: 57.51 Max: 2307.73 Current: 49.62 |
Current Ratio | 1.16 |
85% of the 772 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.56 vs. AGN: 1.16 ) Ranked among companies with meaningful Current Ratio only. |
AGN'
s Current Ratio Range Over the Past 10 Years
Min: 1.03 Med: 2.47 Max: 13.07 Current: 1.16 |
Quick Ratio | 1.06 |
75% of the 772 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.02 vs. AGN: 1.06 ) Ranked among companies with meaningful Quick Ratio only. |
AGN'
s Quick Ratio Range Over the Past 10 Years
Min: 0.8 Med: 2 Max: 11.98 Current: 1.06 |
Days Inventory | 146.91 |
65% of the 765 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 116.78 vs. AGN: 146.91 ) Ranked among companies with meaningful Days Inventory only. |
AGN'
s Days Inventory Range Over the Past 10 Years
Min: 108.18 Med: 125.89 Max: 369.45 Current: 146.91 |
Days Sales Outstanding | 66.38 |
59% of the 699 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 74.10 vs. AGN: 66.38 ) Ranked among companies with meaningful Days Sales Outstanding only. |
AGN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.91 Med: 66.34 Max: 197.04 Current: 66.38 |
Days Payable | 54.63 |
65% of the 640 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 73.92 vs. AGN: 54.63 ) Ranked among companies with meaningful Days Payable only. |
AGN'
s Days Payable Range Over the Past 10 Years
Min: 28.03 Med: 57.39 Max: 109.48 Current: 54.63 |
vs
industry |
vs
history |
||
---|---|---|---|
Dividend Yield % | 1.78 |
57% of the 725 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.53 vs. AGN: 1.78 ) Ranked among companies with meaningful Dividend Yield % only. |
AGN'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.28 Med: 1.02 Max: 1.94 Current: 1.78 |
Forward Dividend Yield % | 1.82 |
57% of the 698 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.60 vs. AGN: 1.82 ) Ranked among companies with meaningful Forward Dividend Yield % only. |
N/A |
5-Year Yield-on-Cost % | 1.79 |
52% of the 889 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.94 vs. AGN: 1.79 ) Ranked among companies with meaningful 5-Year Yield-on-Cost % only. |
AGN'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.28 Med: 1.02 Max: 1.94 Current: 1.79 |
3-Year Average Share Buyback Ratio | -7.50 |
58% of the 540 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -4.80 vs. AGN: -7.50 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
AGN'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6 Med: -6.7 Max: 2 Current: -7.5 |
vs
industry |
vs
history |
||
---|---|---|---|
Price-to-Intrinsic-Value-Projected-FCF | 0.66 | ||
Price-to-Median-PS-Value | 1.59 |
78% of the 692 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.08 vs. AGN: 1.59 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
AGN'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59 Med: 1.79 Max: 5.21 Current: 1.59 |
Earnings Yield (Greenblatt) % | -11.55 |
86% of the 888 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.96 vs. AGN: -11.55 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
AGN'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -12.2 Med: 3 Max: 12.3 Current: -11.55 |
Forward Rate of Return (Yacktman) % | 13.54 |
50% of the 414 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 9.53 vs. AGN: 13.54 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. |
AGN'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.1 Med: 13.3 Max: 22.6 Current: 13.54 |
Revenue (TTM) (Mil) $ | 15,940.70 |
---|---|
EPS (TTM) $ | -13.21 |
Beta | 1.34 |
Volatility | 31.06% |
52-Week Range $ | 142.81 - 256.80 |
Shares Outstanding (Mil) | 345.73 |
Dec18 | Dec19 | Dec20 | |
---|---|---|---|
Revenue (Mil $) | 12,612 | 15,762 | 16,806 |
EBIT (Mil $) | 3,608 | 7,374 | 7,821 |
EBITDA (Mil $) | 7,228 | 7,722 | 8,429 |
EPS ($) | 15.72 | 16.52 | 18.65 |
EPS without NRI ($) | 15.72 | 16.52 | 18.65 |
EPS Growth Rate (Future 3Y To 5Y Estimate) | 8.48% | ||
Dividends per Share ($) | 1.92 | 1.59 | 1.74 |
|
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition Apr 20 2018 - ZACKS |
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR Apr 20 2018 - ZACKS |
Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards? Apr 20 2018 - ZACKS |
GF Chat